Hospital Saturday Fund Hospital Saturday Fund
Facebook Twitter Instagram Linkedin
  • HOME
  • ABOUT US
    • About Us
    • How Are We Funded?
    • HSF health plan
    • Our Patron
    • List of Trustees
    • List of GMC Members
    • Annual Reports
  • APPLY FOR A GRANT
    • Apply for a grant
    • Funding Partners
  • CEO’s BLOG
  • NEWS/GRANT UPDATES
    • Charity News
    • Grant Updates
  • NEWSLETTERS
  • SUPPORT US
    • Support Us
    • Make a Donation
    • Leave a Gift in your Will
    • Matched Funding for Individuals
    • Matched Funding for Corporates
    • Appoint HSF as your Corporate Charity
    • Add HSF to your list
    • Partnerships with Trusts & Foundations
    • Boost your donation – Gift Aid
  • CONTACT US
Hospital Saturday Fund Hospital Saturday Fund
  • HOME
  • ABOUT US
    • About Us
    • How Are We Funded?
    • HSF health plan
    • Our Patron
    • List of Trustees
    • List of GMC Members
    • Annual Reports
  • APPLY FOR A GRANT
    • Apply for a grant
    • Funding Partners
  • CEO’s BLOG
  • NEWS/GRANT UPDATES
    • Charity News
    • Grant Updates
  • NEWSLETTERS
  • SUPPORT US
    • Support Us
    • Make a Donation
    • Leave a Gift in your Will
    • Matched Funding for Individuals
    • Matched Funding for Corporates
    • Appoint HSF as your Corporate Charity
    • Add HSF to your list
    • Partnerships with Trusts & Foundations
    • Boost your donation – Gift Aid
  • CONTACT US
Jan 18

National Eye Research Centre – 13th January 2020

  • 18th January 2020
  • CEO's Blog
Bio laboratory

Paul Clare, Managing Director, HSF health plan is shown around the Bio laboratory

 

On 13th January 2020, Paul Clare and I visited the University of Liverpool to assess a grant application for research into using Melt ElectroWriting (MEW) to treat eye conditions such as glaucoma. The research is supported by the National Eye Research Centre (NERC) and they submitted the grant application.

About The National Eye Research Centre (NERC)
The National Eye Research Centre funds research into the causes and treatments of eye disease, sight loss and blindness. They publish the results of that research in order to stimulate further research advances in ophthalmology. The charity was formed in 1986 and has invested over £14 million into eye research at leading UK centres of excellence in ophthalmology.

Our visit to NERC
I met Laura Serratrice, Chief Executive, NERC, Rachel Williams, Chair in Ocular Biomaterials, University of Liverpool and Dr Lucy Bosworth, Research Fellow. Dr Bosworth gave a presentation about her ground-breaking research into regenerative medicine. Paul and I were also shown some of the scaffolding material and given a comprehensive tour of the Bio laboratory.

Regenerative medicine
Regenerative medicine has enormous potential to treat a multitude of currently incurable conditions – including eye diseases. Technology that allows us to fabricate new tissues to replace those damaged by disease or injury has the power to transform lives – offering real hope to the two million people in the UK who are living with sight loss and a further two million who are predicted to lose their sight by 2050. Coincidentally, HSF has supported a charity called RAFT over a number of years. I have visited RAFT to assess a grant to support tissue reconstruction, which was using the same scaffolding technology as Dr Bosworth.

About Melt ElectroWriting (MEW)
Melt ElectroWriting (MEW) is a new technology, appropriate for regenerative medicine, that manufactures micron-sized* 3D scaffolds, which can be used in tissue engineering to facilitate the growth of cells. To date, this technology has been used to bio-engineer musculoskeletal tissues.

Diagram

Dr Bosworth is the first person to explore its potential for generating ocular biomaterials that could be used to treat conditions such as glaucoma and age-related macular degeneration, or to repair damaged corneas.

Glaucoma
Glaucoma is the name for a group of eye conditions that cause damage to the optic nerve, leading to vision loss. In most cases, the damage is caused by increased pressure within the eye, resulting from a build-up of fluid called aqueous humour. This fluid is produced in the eye and performs many vital functions including protecting the cornea from disease, dust or pollen. In a healthily functioning eye, the trabecular meshwork helps to maintain normal eye pressure by allowing aqueous humour to drain out of the eye into the vascular system.

Ageing and disease can lead to progressive cell loss, which causes the trabecular meshwork’s sieve-like structure to become blocked, restricting fluid outflow. This causes pressure in the eye to rise, which triggers compression of the optic nerve, resulting in glaucoma.

Currently, there are no regenerative therapies available to treat this condition. MEW will allow the team at Liverpool to fabricate scaffolds with specific dimensions and porosities on which they will grow cells that can be engineered to behave like healthy, functioning trabecular meshwork cells. The ultimate aim will be to implant this cell-loaded scaffold into the eye to restore the fluid outflow pathway.

Using MEW to research Conjunctiva repair
The conjunctiva is a clear, thin membrane that lines the white of the eye and the inside of the eyelids. Its primary function is to keep the front surface of the eye and the inner surfaces of the eyelids moist and lubricated so that the eye can open and close without friction or irritation.

Goblet cells, which are spread throughout the conjunctiva, play a key role in this process. These specialist cells produce mucins – a slimy material that forms part of the tear fluid and provides a protective coating to the outer surface of the eye. Mucins are spread evenly over the eye’s surface by eyelid movement during blinking.

The conjunctiva is susceptible to damage from disease and traumas caused by chemical burns or side effects from contact with medications (e.g. glaucoma medication). Scarring and prolonged inflammation of the conjunctiva can lead to persistent discomfort, ocular surface failure, and corneal disease.

Transplants can be used to treat corneal disease but only if the conjunctiva is healthy and at present, there is no reliable method for replacing and restoring the conjunctiva. Dr Bosworth has been amazed by how the stability of the MEW scaffolding has led to healthy Goblet cell growth producing large amounts of mucins.

It is hoped, that eventually, MEW technology might be used to produce a full cornea which could be used for medical research.

Looking ahead
NERC are looking to raise £20K towards MEW equipment which will be brought from Brisbane in Australia. We look forward to further updates from NERC on using Melt ElectroWriting (MEW) to treat eye conditions.

To learn more about NERC, please visit their website: https://www.nercuk.org/

Comments are closed.

Featured Posts

The Cork Reception November 2022
The Cork Reception November 2022

15th December 2022

The Big Give Christmas Challenge 2022
The Big Give Christmas Challenge 2022

14th December 2022

Cork Life Centre
Cork Life Centre

14th December 2022

Chelsea Football Club Foundation
Chelsea Football Club Foundation

5th December 2022

Emmanuel Cancer Reaserch Foundation Malta
Emmanuel Cancer Reaserch Foundation Malta

29th November 2022

The Malta Trust Foundation
The Malta Trust Foundation

29th November 2022

The Hospital Saturday Fund AGM May 2022
The Hospital Saturday Fund AGM May 2022

17th May 2022

British Tinnitus Association
British Tinnitus Association

14th January 2022

The Big Give Christmas Challenge 2021
The Big Give Christmas Challenge 2021

3rd December 2021

Pancreatic Cancer UK
Pancreatic Cancer UK

30th September 2021

previous arrow
next arrow

Categories

  • CEO's Blog
  • Charity News
  • Grant Update

All Posts

  • The Cork Reception November 2022

    The Cork Reception November 2022

    15th December 2022
  • The Big Give Christmas Challenge 2022

    The Big Give Christmas Challenge 2022

    14th December 2022
  • Cork Life Centre

    Cork Life Centre

    14th December 2022
  • Chelsea Football Club Foundation

    Chelsea Football Club Foundation

    5th December 2022
  • Emmanuel Cancer Reaserch Foundation Malta

    Emmanuel Cancer Reaserch Foundation Malta

    29th November 2022
  • The Malta Trust Foundation

    The Malta Trust Foundation

    29th November 2022
  • The Hospital Saturday Fund AGM May 2022

    The Hospital Saturday Fund AGM May 2022

    17th May 2022
  • British Tinnitus Association

    British Tinnitus Association

    14th January 2022
  • The Big Give Christmas Challenge 2021

    The Big Give Christmas Challenge 2021

    3rd December 2021
  • Pancreatic Cancer UK

    Pancreatic Cancer UK

    30th September 2021
  • Disabled Sailors Association

    Disabled Sailors Association

    30th September 2021
  • University of Plymouth – Antibiotics Accelerator

    University of Plymouth – Antibiotics Accelerator

    30th September 2021
  • Stella Hancock Driving Group

    Stella Hancock Driving Group

    9th August 2021
  • June 2021 ‘pupdate’ from Uhtred

    June 2021 ‘pupdate’ from Uhtred

    4th August 2021
  • Visit to The Scuba Trust – June 2021

    Visit to The Scuba Trust – June 2021

    24th June 2021
  • Heartburn Cancer UK update

    Heartburn Cancer UK update

    16th June 2021
  • A “pupdate” from Uhtred

    A “pupdate” from Uhtred

    6th April 2021
  • Irish Dogs for the Disabled grant

    Irish Dogs for the Disabled grant

    16th March 2021
  • Young Epilepsy grant

    Young Epilepsy grant

    16th March 2021
  • Leicestershire Multiple Sclerosis Therapy Centre grant

    Leicestershire Multiple Sclerosis Therapy Centre grant

    9th March 2021

USING OUR SITE

  • Privacy Policy
  • Website Terms and Conditions
  • GDPR Cookie Policy

SOCIAL ACCOUNTS

Facebook Twitter Instagram Linkedin

Contact Information

The Hospital Saturday Fund, 24 Upper Ground, London. SE1 9PD. Phone: 020 7202 1365 E-Mail: charity@hsf.eu.com

CHARITY DETAILS

The Hospital Saturday Fund

Registered Charity in the UK No 1123381 and in Ireland No 20104528

Registered Office: 24 Upper Ground, London SE1 9PD

President: The Lord Mayor of London

Chief Executive: Paul W Jackson MSc BA(Hons) DChA

Annual Reports

  • Annual Reports
© 2022 The Hospital Saturday Fund